After hosting investor meetings with management, Piper Jaffray analyst Danielle Brill sees near-term upside in shares of Acceleron Pharma. The analyst came away "more bullish on the name," saying she expects positive luspatercept Phase 2 data in myelofibrosis in early November. Brill expects 2020 to be a "transformative year" for Acceleron with the launch of luspatercept in transfusion dependent B-thalassemia and seocnd line myelodysplastic syndromes. Luspatercept should become a multibillion dollar drug with label expansion into various other anemias, says the analyst, who keeps an Overweight rating on Acceleron with a $71 price target.